About

Dr. Jennifer Buell joined the Agenus board in 2024 and has chaired the company's Executive Council since 2023. She has served as President and Chief Executive Officer of MiNK Therapeutics, a publicly traded Agenus affiliate, since 2021, and brings more than 27 years of biopharmaceutical experience advancing programs from discovery through clinical development and commercialization.

From 2018 to 2021 she was President and Chief Operating Officer of Agenus, responsible for operations, investor relations and external affairs, and she has held a range of earlier roles at the company. Prior to Agenus she held R&D operations leadership positions at Bristol-Myers Squibb and the Harvard Clinical Research Institute (now the Baim Institute). She holds a Ph.D. in Cellular, Biochemical and Molecular Biochemistry and an M.S. in Biostatistics from Tufts University.

Roles

Agenus Inc.
Director; Chairman of the Executive Council · Current role
2024–present
Agenus Inc.
President and Chief Operating Officer · Responsible for operations, investor relations and external affairs
2018–2021
Agenus Inc.
Chief Communications and External Affairs Officer
2017–2018
Agenus Inc.
Vice President, Research and Development Operations and Program Management · Role expanded to include external affairs from 2016 to 2017
2013–2016
Bristol-Myers Squibb
R&D operations leadership
—
Harvard Clinical Research Institute (now Baim Institute)
R&D operations leadership
—

External Roles

MiNK Therapeutics, Inc.
President and Chief Executive Officer
since 2021
Protagenic Therapeutics, Inc.
Director
since July 2020

Fixed Compensation

Performance Compensation

Director Compensation

FY 2025
Board compensation
$0
NoteAs Chairman of the Executive Council, Dr. Buell received no additional compensation for her board service in 2025

Also at Agenus Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.